ClinicalTrials.Veeva

Menu

Randomized and Controlled Clinical Trial to Evaluate Bacterial Adhesion on Multi-Im® Transepithelial Components

F

Fundación Eduardo Anitua

Status

Completed

Conditions

Biofilm Formation

Treatments

Device: Multi-Im Ti-Golden transepithelial component
Device: Multi-Im Nanogolden transepithelial component
Device: Multi-Im Machined transepithelial component.

Study type

Interventional

Funder types

Other

Identifiers

NCT03554876
FIBEA-06-EC/17/Multi-Im

Details and patient eligibility

About

This study evaluates the efficacy of Mutli-Im® transepithelial components in the inhibition of bacterial adhesion.

The control group will be the Multi-Im® transepithelial component with the conventional surface (Multi-IM® Machined) and the experimental group will be the Multi-Im transepithelial components with the Ti-Golden® surface (Multi-Im Golden) or with the nanogolden surface (Multi-Im® nanogolden). Periodontal indices and biofilformation will be assessed during 2 months after implant loading. Metagenomic analysis and PCR technique will be implemented to assess the biofilm formation.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Indication of having to place at least three dental implants.
  • Plate index ≤ 20% and absence of evidence of active periodontal disease.
  • Bleeding index of adjacent teeth ≤ 30%.
  • Probing depth in adjacent teeth <4 mm.
  • Not having used systemic antibiotics during the last 6 months.
  • Non smoker.
  • Possibility for observation during the treatment period.
  • Having signed the informed consent.

Exclusion criteria

  • Suffering any alteration or serious hematologic disease.
  • Being undergoing or having received in the 30 days prior to inclusion:

radiotherapy, chemotherapy or immunosuppressive treatments, systemic corticosteroids and/or anticoagulants.

  • Presence of malignant tumors, hemangiomas or angiomas in the area of implant placement.
  • Patients undergoing treatment with bisphosphonate drugs, both orally and intravenously.
  • Metabolic bone disease.
  • Diseases that affect the oral mucosa.
  • Diabetic patients.
  • Severe parafunctional habits and/or temporomandibular joint disorders.
  • Pregnant or lactating women.
  • Physical or mental inability to maintain a good oral hygiene.
  • Being participating in another study.
  • In general, any inability to participate in the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

17 participants in 3 patient groups

Multi-Im Machined
Active Comparator group
Description:
Multi-Im Machined
Treatment:
Device: Multi-Im Machined transepithelial component.
Multi-Im® nanogolden
Experimental group
Description:
Multi-Im® nanogolden
Treatment:
Device: Multi-Im Nanogolden transepithelial component
Multi-Im T-Golden
Experimental group
Description:
Multi-Im T-Golden
Treatment:
Device: Multi-Im Ti-Golden transepithelial component

Trial contacts and locations

1

Loading...

Central trial contact

Mohammad Hamdan, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems